Abstract
CD4 + tissue-resident memory T (T RM ) cells contribute to host defense and to the pathogenesis of chronic inflammatory diseases, but the molecules that direct their differentiation are unknown. We found that the transcription factor hepatic leukemia factor (HLF) could direct the tissue residency program and function of CD4 + T RM cells. HLF simultaneously up-regulated tissue retention receptors, down-regulated tissue egress receptors, and promoted proinflammatory CD4 + T RM cells by inducing Bhlhe40 , and all of these processes were associated with changes in chromatin accessibility. Genetic deletion of Hlf inhibited CD4 + T RM cell generation and ameliorated airway tissue inflammation in vivo. HLF + CD4 + T RM cells isolated from inflamed airway tissue in humans had a tissue residency signature and expressed inflammatory cytokines. We conclude that HLF may act as a central regulator of proinflammatory CD4 + T RM cell development and function.
Funding Information
  • Naito Foundation
  • Takeda Science Foundation
  • Ministry of Education, Culture, Sports, Science, and Technology: Grants-in-Aid for Scientific Research (19H05650)
  • Ministry of Education, Culture, Sports, Science, and Technology: Grants-in-Aid for Scientific Research (20H03685)
  • Ministry of Education, Culture, Sports, Science, and Technology: Grants-in-Aid for Scientific Research (23H02916)
  • Ministry of Education, Culture, Sports, Science, and Technology: Grant-in-Aid for Young Scientists (19K16683)
  • Ministry of Education, Culture, Sports, Science, and Technology: Grant-in-Aid for Young Scientists (22K15485)
  • MSD Life Science Foundation
  • Ministry of Education, Culture, Sports, Science, and Technology: Transformative Research Areas (21H05120)
  • Japan Agency for Medical Research and Development (AMED): Practical Research Project for Allergic Diseases and Immunology (21ek0410060h0003)
  • Japan Agency for Medical Research and Development (AMED): AMED-CREST (23gm1210003h0006)
  • Japan Agency for Medical Research and Development (AMED): Research Program on Emerging and Re-emerging Infectious Diseases (JP23fk0210134)
  • Japan Agency for Medical Research and Development (AMED): Vaccine Development Support Program (JP243fa627009)
  • Japan Agency for Medical Research and Development (AMED): Research Program on Emerging and Re-emerging Infectious Diseases (JP24gm1810010)
  • Ministry of Education, Culture, Sports, Science, and Technology: Transformative Research Areas (21H05121)
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Japan Agency for Medical Research and Development (AMED): Practical Research Project for Allergic Diseases and Immunology (19ek0410045h0003)
  • Japan Agency for Medical Research and Development (AMED): Practical Research Project for Allergic Diseases and Immunology (22ek0410082h0003)
  • Japan Agency for Medical Research and Development (AMED): Practical Research Project for Allergic Diseases and Immunology (24ek0410092h0003)
  • Japan Agency for Medical Research and Development (AMED): AMED-PRIME (20gm6110005h0004)
  • Japan Agency for Medical Research and Development (AMED): AMED-CREST (24gm1810009h0002)
  • Japan Agency for Medical Research and Development (AMED): AMED-SCARDA (Synergy Institute fro Futuristic Mucoasl Vaccine Research and Development (243fa627003h0003)
  • Japan Science and Technology Agency (JPMJFR200R)
  • Japan Agency for Medical Research and Development (AMED): AMED-LEAP (Leading Advanced Projects for medical innovation (JP24gm0010011)
  • Early-Stage Medical and Pharmaceutical Research Grant, Chiba University Future Medicine Education and Research Organization
  • Future Medicine Grant Program, Chiba University Future Medicine Fund

This publication has 78 references indexed in Scilit: